Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomericaBMRA -6.28%50 Receivables Turnover is 1.05 as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Biomerica ranks worse than 71.27% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biomerica's Revenue for the
three
months ended in Feb. 2026 was $0.99 Mil. Biomerica's average Accounts Receivable for the
three
months ended in Feb. 2026 was $0.94 Mil.
Hence, Biomerica's Receivables Turnover for the
three
months ended in Feb. 2026 was 1.05.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biomerica Receivables Turnover Related Terms
Biomerica Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Biomerica's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMRA vs WOK, ALURD, ITOC: Receivables Turnover Comparison
For the Medical Devices subindustry, Biomerica's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomerica Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biomerica's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomerica (BMRA) has a Receivables Turnover of 1.05 as of Feb. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biomerica and its competitors. According to the industry distribution chart, Biomerica ranks #578 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is Biomerica's Receivables Turnover too high?
Biomerica's current Receivables Turnover is 1.05. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Biomerica's value of 1.05 is 80.9% below this industry median. Based on the distribution chart, Biomerica ranks #578 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Receivables Turnover compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #578 out of 811 companies for Receivables Turnover. This places Biomerica in the lower half of its industry. The industry median Receivables Turnover is 5.51. Biomerica's value of 1.05 is 80.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomerica's current Receivables Turnover of 1.05 is 80.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biomerica and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomerica's current Receivables Turnover is 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Receivables Turnover is 1.05 and 80.9% below the Medical Devices & Instruments industry median of 5.51. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biomerica (BMRA), the current Receivables Turnover is 1.05 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomerica (BMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Biomerica stock appears to be undervalued.
The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18.
GuruFocus considers Biomerica to be Possible Value Trap.
Key valuation signals for BMRA:
Receivables Turnover: 1.05
GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
Industry Position: 80.9% below the Medical Devices & Instruments median (#578 of 811)
No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score
Get the complete analysis for BMRA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRA has been successfully added to your 
